| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Tumor Virology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan
B cell Ag receptor (BCR) cross-linking with anti-Ig Abs efficiently induces activation of latently infected EBV in some B cell lines, but not in others. The present study was aimed at defining the molecular mechanisms that determine the response to BCR-mediated EBV activation. Comparison of Burkitt’s lymphoma-derived Akata, Mutu-I, and Daudi cells, which are representative responders and nonresponders to BCR-mediated EBV activation, respectively, indicated that three signaling pathways, phosphatidylinositol 3-kinase (PI3K), extracellular signal-regulated kinase (ERK), and p38 mitogen-activated protein kinase (MAPK), were activated in anti-Ig-treated Akata and Mutu-I cells. However, in anti-Ig-treated Daudi cells PI3K was not activated, ERK was faintly activated, and p38 MAPK was constitutively phosphorylated irrespective of anti-Ig treatment. Restoration of PI3K activity with insulin-like growth factor 1 restored ERK and p38 MAPK pathways, and was accompanied by EBV activation in anti-Ig-treated Daudi cells. In contrast, a specific inhibitor for PI3K, wortmannin, inhibited EBV activation by anti-Ig Abs in Akata and Mutu-I cells. Transfection assays in EBV-negative Daudi cells revealed that PI3K activated a promoter for BZLF1, which is a switch of EBV activation from a latent infection, in the absence of other EBV products suggesting that the BZLF promoter was a target of BCR signaling, and that PI3K was important for BCR-mediated BZLF1 activation. These results indicate that the absence of PI3K impedes the progression of signals through the BCR and becomes a determinant of unresponsiveness to BCR-mediated EBV activation.
This article has been cited by other articles:
|
|
 |
|
  K. R. Katsumura, S. Maruo, Y. Wu, T. Kanda, and K. Takada Quantitative evaluation of the role of Epstein-Barr virus immediate-early protein BZLF1 in B-cell transformation J. Gen. Virol., October 1, 2009; 90(10): 2331 - 2341. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Oussaief, A. Hippocrate, V. Ramirez, A. Rampanou, W. Zhang, D. Meyers, P. Cole, R. Khelifa, and I. Joab Phosphatidylinositol 3-Kinase/Akt Pathway Targets Acetylation of Smad3 through Smad3/CREB-binding Protein Interaction: CONTRIBUTION TO TRANSFORMING GROWTH FACTOR {beta}1-INDUCED EPSTEIN-BARR VIRUS REACTIVATION J. Biol. Chem., September 4, 2009; 284(36): 23912 - 23924. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Dussault, E. Ducas, C. Racine, A. Jacques, I. Pare, S. Cote, and S. Neron Immunomodulation of human B cells following treatment with intravenous immunoglobulins involves increased phosphorylation of extracellular signal-regulated kinases 1 and 2 Int. Immunol., November 1, 2008; 20(11): 1369 - 1379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Wen, D. Iwakiri, K. Yamamoto, S. Maruo, T. Kanda, and K. Takada Epstein-Barr Virus BZLF1 Gene, a Switch from Latency to Lytic Infection, Is Expressed as an Immediate-Early Gene after Primary Infection of B Lymphocytes J. Virol., January 15, 2007; 81(2): 1037 - 1042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Emura, D. Saito, T. Kakizoe, and M. J. Blaser Infection, Cancer and Prevention: Report of the 19th International Symposium of the Foundation for Promotion of Cancer Research Jpn. J. Clin. Oncol., November 1, 2006; 36(11): 745 - 755. [Full Text] [PDF]
|
|
|
|
|
|
J. Yuan, E. Cahir-McFarland, B. Zhao, and E. Kieff Virus and Cell RNAs Expressed during Epstein-Barr Virus Replication J. Virol., March 1, 2006; 80(5): 2548 - 2565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Huang, G. Liao, H. Chen, F. Y. Wu, L. Hutt-Fletcher, G. S. Hayward, and S. D. Hayward Contribution of C/EBP Proteins to Epstein-Barr Virus Lytic Gene Expression and Replication in Epithelial Cells J. Virol., February 1, 2006; 80(3): 1098 - 1109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Daibata, K. Bandobashi, M. Kuroda, S. Imai, I. Miyoshi, and H. Taguchi Induction of Lytic Epstein-Barr Virus (EBV) Infection by Synergistic Action of Rituximab and Dexamethasone Renders EBV-Positive Lymphoma Cells More Susceptible to Ganciclovir Cytotoxicity In Vitro and In Vivo J. Virol., May 1, 2005; 79(9): 5875 - 5879. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
